

authority is contingent on Respondent being a practitioner with a valid DEA registration, *see* 21 U.S.C. 823(g)(2)(A); 21 CFR 1301.28(a), I will revoke his DATA-Waiver authority as well.

Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BZ5641419 and DATA-Waiver Identification Number XZ5641419, issued to Witold Marek Zajewski, M.D., be, and they hereby are, revoked. I further order that any pending application of Witold Marek Zajewski to renew or modify the above registration, or any pending application of Witold Marek Zajewski for any other

registration in the State of Illinois, be, and it hereby is, denied. This Order is effective immediately.⁴

Dated: April 4, 2018.
Robert W. Patterson,
Acting Administrator.
 [FR Doc. 2018-07454 Filed 4-10-18; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION:

The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

| Company | FR docket | Published |
|--|------------------|--------------------|
| Sharp (Bethlehem), LLC | 83 FR 539 | January 4, 2018. |
| Catalent Pharma Solutions, LLC | 83 FR 2215 | January 16, 2018. |
| Janssen Pharmaceuticals, Inc | 83 FR 2214 | January 16, 2018. |
| Mylan Pharmaceuticals, Inc | 83 FR 5809 | February 9, 2018. |
| Meridian Medical Technologies, Inc | 83 FR 5810 | February 9, 2018. |
| Noramco, Inc | 83 FR 5810 | February 9, 2018. |
| Johnson Matthey, Inc | 83 FR 5811 | February 9, 2018. |
| Mylan Technologies, Inc | 83 FR 5811 | February 9, 2018. |
| Mylan Pharmaceuticals, Inc | 83 FR 8107 | February 23, 2018. |

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance

with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies.

Dated: April 4, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
 [FR Doc. 2018-07444 Filed 4-10-18; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION:

The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

| Company | FR docket | Published |
|------------------------------------|-------------------|--------------------|
| Nanosyn, Inc | 82 FR 56993 | December 1, 2017. |
| Janssen Pharmaceutical, Inc | 82 FR 58027 | December 8, 2017. |
| Cambrex High Point, Inc | 82 FR 61795 | December 29, 2017. |
| AMPAC Fine Chemicals LLC | 82 FR 61795 | December 29, 2017. |
| Organix, Inc | 83 FR 150 | January 2, 2018. |
| Johnson Matthey Inc | 83 FR 2215 | January 16, 2018. |
| Chemtos, LLC | 83 FR 2671 | January 18, 2018. |
| Alcami Wisconsin Corporation | 83 FR 2675 | January 18, 2018. |

⁴ For the same reasons which led the IDFPFR to revoke Respondent's controlled substance license, I

conclude that the public interest necessitates that

this Order be effective immediately. 21 CFR 1316.67.